Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Giving chemotherapy and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related or unrelated donor, that closely matches the patient's blood, are infused into the patient they may help the patient's bone marrow to make stem cells, red blood cells, white blood cells, and platelets.

PURPOSE: This phase II trial is studying how well donor bone marrow transplant works in treating patients with leukemia, lymphoma, or nonmalignant hematologic disorders.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
• Collaborator: National Cancer Institute (NCI)
• Treatments: Cyclophosphamide

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed diagnosis of one of the following:

• Acute lymphocytic leukemia (ALL):

• Complete remission (CR) 1 - high risk defined as overt CNS involvement or poor cytogenetics (additions, deletions, translocations, or multiple abnormalities)

• CR2

• Induction failures

• Relapse - patients with at least 10% marrow blasts undergo at least one reinduction attempt

• Acute myelogenous leukemia (AML):

• CR1 - high risk defined as poor cytogenetics (deletions, additions, multiple abnormalities)

• CR2

• Induction failures

• Relapse - patients with at least 10% marrow blasts undergo at least one reinduction attempt

• Chronic myelogenous leukemia (CML):

• Chronic phase (CP) 1

• Accelerated phase/CP2 - patients in blast phase must undergo treatment and achieve a second chronic phase prior to transplant

• Chronic lymphocytic leukemia (CLL):

• Relapse - any stage; must have received no more than 3 prior regimens

• Multiple myeloma:

• At diagnosis - primary refractory

• Relapse (no more than 2) - sensitive disease

• Plasma cell leukemia

• Inability to achieve a complete remission after autologous transplant (no older than 40)

• Myelodysplasia - all subtypes

• Myeloproliferative disorders - patients with poor response to medical therapy or cytogenetic abnormalities

• Severe aplastic anemia (SAA):

• Very SAA - at diagnosis

• SAA - induction therapy

• Donors must be a phenotypic (6 out of 6) match or a one antigen (A or B) mismatch

PATIENT CHARACTERISTICS:

Age:

• 15 to 50

Performance status:

• Karnofsky 80-100%

Life expectancy:

• Not specified

Hematopoietic:

• See Disease Characteristics

Hepatic:

• Bilirubin no greater than 2.0 mg/dL

• SGOT and SGPT no greater than 3 times normal

• PT/PTT normal

Renal:

• Creatinine no greater than 2.0 mg/dL

• Creatinine clearance at least 60 mL/min

Cardiovascular:

• Left ventricular ejection fraction at least 45%

• No myocardial infarction within past 6 months

• No uncontrolled arrhythmias

Pulmonary:

• FEV1 at least 50%

• DLCO at least 50% predicted

Other:

• No active serious infection

• HIV negative

• Not pregnant or nursing

• No uncontrolled diabetes mellitus or thyroid disease

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• See Disease Characteristics

Chemotherapy:

• See Disease Characteristics

Endocrine therapy:

• Not specified

Radiotherapy:

• Not specified

Surgery:

• Not specified